The seventh edition of the non-small cell lung cancer (NSCLC) TNM staging system was
developed by the International Association for the Staging of Lung Cancer (IASLC) Lung …

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant
therapy guideline for resected non–small-cell lung cancers. Methods ASCO convened an …

Importance The prevalence of early-stage non–small cell lung cancer (NSCLC) is expected
to increase with recent implementation of annual screening programs. Reliable prognostic …

Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Successful treatment decisions in cancer depend on the accurate assessment of patient risk.
To improve our understanding of the molecular alterations that underlie deadly …

Breast cancer is a heterogeneous disease comprising the estrogen receptor (ER)–positive
luminal subtype which is subdivided into luminal A and luminal B and ER-negative breast …

The growth of a tumor depends to a certain extent on an increase in mitotic events. Key
steps during mitosis are the regulated assembly of the spindle apparatus and the separation …

The prognosis and prediction of adjuvant chemotherapy (ACT) response in early-stage non-
small cell lung cancer (NSCLC) patients remain poor in this era of personalized medicine …

An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes
predictive of outcome, improving diagnostic precision beyond clinical descriptors such as …

The impact of the tumor immune microenvironment on overall survival in non‐small cell lung
cancer (NSCLC) has been studied, but there is little information on its relevance for risk of …